NCT07058389 Synergy Between Physical Activity and Outdoor Green Environments to Reduce the Intensity of Negative Symptoms in Schizophrenia.
| NCT ID | NCT07058389 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne |
| Condition | Schizoaffective Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2025-10-07 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2025-10-07 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Physical activity appears to be a novel and original adjunctive therapeutic approach in the management of patients with schizophrenia. It may help reduce schizophrenic symptoms, act as a pro-cognitive therapy, improve quality of life, and reduce cardiovascular comorbidities. Moreover, some evidence suggests that physical activity practiced in a natural environment has even more positive effects on mental health compared to physical activity carried out indoors or in urban settings. Indeed, greater exposure to greenery is associated with a better perception of general health and with reduced levels of cortisol, anxiety, and depression. No study has yet attempted to examine the impact of physical activity in green (outdoor) spaces compared to indoor physical activity on the negative symptoms of patients suffering from schizophrenia. The aim of this study is therefore to test this hypothesis.
Eligibility Criteria
Inclusion Criteria: * Patients with schizophrenia, aged 18 to 55 years * Having persistent negative symptoms (SNS), negative symptoms self-assessment scale \> 7 * Regularly monitored in the psychiatry department. * Have no medical contraindications to physical activity * Subject affiliated with or entitled to a social security system. * Subject having received informed information about the study and having co-signed, with the investigator, consent to participate in the study. * Male or female. Exclusion Criteria: * Patient unsuitable for study in the opinion of the investigator * Any subject with chronic joint pathologies (example: repeated sprains, patellar or ligament problems) or cardiac pathologies. * Any subject presenting chronic or central neurological pathologies. * Any subject deprived of liberty or subject to legal protection * Excessive consumption of alcohol (\> 14 glasses per week) or caffeinated drinks (\> 400 mg of coffee per day). * Pregnant women. * Subject unable to understand the purpose and conditions of the study, unable to give consent.
Contact & Investigator
Medhi HOUSNI, Md
PRINCIPAL INVESTIGATOR
CHU de Saint-Etienne
Frequently Asked Questions
Who can join the NCT07058389 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Schizoaffective Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07058389 currently recruiting?
Yes, NCT07058389 is actively recruiting participants. Contact the research team at Mehdi.Housni@chu-st-etienne.fr for enrollment information.
Where is the NCT07058389 trial being conducted?
This trial is being conducted at Saint-Etienne, France.
Who is sponsoring the NCT07058389 clinical trial?
NCT07058389 is sponsored by Centre Hospitalier Universitaire de Saint Etienne. The principal investigator is Medhi HOUSNI, Md at CHU de Saint-Etienne. The trial plans to enroll 45 participants.